Advance the clinical development of oxfendazole as an anti-parasitic macrofilaricidal treatment
current phase of drug development
updated 16 Feb 2023
Screening of drug libraries obtained from biotech and pharmaceutical companies, along with active screening of the literature, identified oxfendazole, a veterinary product used for deworming in animals, as a potential macrofilaricidal treatment for river blindness.
Based on highly encouraging pre-clinical data on the efficacy of oxfendazole, DNDi is evaluating the use of oxfendazole for filarial infections. DNDi is moving ahead with pharmaceutical development of the drug, and the HELP Consortium, of which DNDi is a member, is conducting a Phase I clinical trial.
HELP Consortium: an international network to speed up identification of new treatments for worm-related diseases
Launched in 2019, the Helminth Elimination Platform (HELP) led by the Swiss Tropical and Public Health Institute (Swiss TPH) convenes key players in research and development for filarial diseases. The multidisciplinary consortium works to identify new treatments against nematode worms, including onchocerciasis, lymphatic filariasis, hookworm, and whipworm.
News & resources
- 21 November 2023 - 코오롱생명과학, 국제 소외질환신약개발재단과 ‘회선사상충’ 개발 협약, The Chosun Ilbo
- 21 November 2023 - DNDi, 소외계층 신약 개발 파트너로 코오롱생명과학 택한 이유는, E Daily
- 7 April 2023 - eWHORM project launched to eliminate worm infections in Sub Saharan Africa
- 19 October 2022 - Comparison of the macrofilaricidal efficacy of oxfendazole and its isomers against the rodent filaria Litomosoides sigmodontis, Frontiers in Tropical Diseases
- 6 July 2020 - Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro, PLOS Neglected Tropical Diseases
Get our latest news, personal stories, research articles, and job opportunities.